DelveInsight’s “Overactive Bladder Market Insights, Epidemiology, and Market Forecast-2032″ report delivers an in-depth understanding of the Overactive Bladder, historical and forecasted epidemiology as well as the Overactive Bladder market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Overactive Bladder market report provides current treatment practices, emerging drugs, Overactive Bladder market share of the individual therapies, and current and forecasted Overactive Bladder market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Overactive Bladder treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Overactive Bladder market.
Some of the key facts of the Overactive Bladder Market Report
Increased symptom severity or bother appears to be a driving force for patients to seek treatment. According to data from the EpiLUTS study in the USA, both men and women with bothersome OAB were more likely to have sought treatment from a healthcare professional than those either without bother (men: 35 vs. 19 %, p < .001; women: 27 vs. 13 %, p <.001) or without OAB (men: 35 vs. 4 %, p< .001; women: 27 vs. 4 %, p< .001).
Similarly, both men and women with bothersome OAB from the EPIC study reported initiating a conversation about their symptoms with a healthcare provider (52 vs. 22 % of those without bother, p<0.05) [19]. In addition, those who did initiate a conversation were more likely to be older than 50 years (OR 1.5; 95 % CI, 1.2–2.0), complain of UI (OR 1.5; 95 % CI, 1.1–2.0), report duration of OAB symptoms of more than 4 years (OR 1.9; 95% CI, 1.5–2.5), and have had a doctor visit in the previous 6 months for any reason (OR 2.8; 95% CI, 2.0–3.9). Men were more likely than women to initiate a conversation about their symptoms (OR 1.6; 95 % CI, 1.2–2.2).
Got queries? Click here to know more about the Overactive Bladder Market Landscape
Overactive Bladder Overview
Overactive bladder, also called OAB, causes a frequent and sudden urge to urinate that may be difficult to control. You may feel like you need to pass urine many times during the day and night, and may also experience unintentional loss of urine (urgency incontinence).
Symptoms include Feeling a sudden urge to urinate that’s difficult to control Experience unintentional loss of urine immediately after an urgent need to urinate (urgency incontinence). Urinate frequently, usually eight or more times in 24 hours wake up more than two times in the night to urinate (nocturia). Several conditions may contribute to signs and symptoms of overactive bladder, including Neurological disorders, such as stroke and multiple sclerosis Diabetes. Urinary tract infections can cause symptoms similar to those of an overactive bladder Hormonal changes during menopause in women. Conditions affecting the bladder, such as tumors or bladder stones. These healthy lifestyle choices may reduce your risk of overactive bladderMaintain a healthy weight Get regular, daily physical activity and exercise. Limit caffeine and alcohol. Quit smoking. Manage chronic conditions, such as diabetes, that might contribute to overactive bladder symptoms. Do exercises to make the pelvic floor muscles stronger. These exercises are called Kegel exercises.
Overactive Bladder Epidemiology Insights:
Defined by the presence of urinary urgency at least “sometimes” and/or urge-UI, 43 % of female and 27 % of male respondents reported OAB. With a more restrictive definition of at least “often,” the prevalence of OAB was 33 % for women and 16 % for men.
For men, only 60.9 % of those with OAB met physical activity guidelines (compared to 67.5 % without OAB, p < .001) and 46.1 % met 2010 Healthy People objectives (compared to 54.3 % without OAB, p< .001). For women, 50.1 % of those with OAB met physical activity guidelines (vs. 58.1 % of those without OAB, p< .0001) and 34.7 % met 2010 Healthy People initiatives (vs. 45.2 % of those without OAB, p < .0001).
Unemployment was higher for those with OAB than without (men: 43.6 vs. 24.2 %, p < .0001; women: 54.1 vs. 41.4 %, p <.0001) and remained significant when controlled for multiple variables in men (OR 1.48; 95 % CI, 1.2–1.8), but not women (OR 1.12; 95 % CI, 0.95–1.32).
Overactive Bladder Epidemiology Segmentation
Overactive Bladder diagnosed cases
Overactive Bladder gender-specific cases
Overactive Bladder treated cases
Overactive Bladder Market Outlook
The Overactive Bladder market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Overactive Bladder market trends by analyzing the impact of current Overactive Bladder therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
This segment gives a thorough detail of the Overactive Bladder market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Overactive Bladder market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Overactive Bladder market in 7MM is expected to witness a major change in the study period 2019-2032.
Overactive Bladder Key Companies
AbbVie,
Medytox
Velicept Therapeutics,
Sumitovant Biopharma
Hugel
Imbrium Therapeutics
And many more
Table of Contents
Key Insights
Report Introduction
Executive Summary of Overactive Bladder
Disease Background and Overview
Epidemiology and patient population
The United States
EU 5
Overactive Bladder Emerging Therapies
Market Access and Reimbursement of Therapies
Appendix
Overactive Bladder Report Methodology
DelveInsight Capabilities
Disclaimer
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Adya KaulEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
